124 related articles for article (PubMed ID: 38062554)
21. DCLK1 phosphorylates the microtubule-associated protein MAP7D1 to promote axon elongation in cortical neurons.
Koizumi H; Fujioka H; Togashi K; Thompson J; Yates JR; Gleeson JG; Emoto K
Dev Neurobiol; 2017 Apr; 77(4):493-510. PubMed ID: 27503845
[TBL] [Abstract][Full Text] [Related]
22. Doublecortin-like kinase 1 is a therapeutic target in squamous cell carcinoma.
Standing D; Arnold L; Dandawate P; Ottemann B; Snyder V; Ponnurangam S; Sayed A; Subramaniam D; Srinivasan P; Choudhury S; New J; Kwatra D; Ramamoorthy P; Roy BC; Shadoin M; Al-Rajabi R; O'Neil M; Gunewardena S; Ashcraft J; Umar S; Weir SJ; Tawfik O; Padhye SB; Biersack B; Anant S; Thomas SM
Mol Carcinog; 2023 Feb; 62(2):145-159. PubMed ID: 36218231
[TBL] [Abstract][Full Text] [Related]
23. Role of DCLK1 in oncogenic signaling (Review).
Lu Q; Feng H; Chen H; Weygant N; Du J; Yan Z; Cao Z
Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36148883
[TBL] [Abstract][Full Text] [Related]
24. Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical β-catenin-dependent mechanism.
Ali N; Nguyen CB; Chandrakesan P; Wolf RF; Qu D; May R; Goretsky T; Fazili J; Barrett TA; Li M; Huycke MM; Bronze MS; Houchen CW
Sci Rep; 2020 Jun; 10(1):10578. PubMed ID: 32601309
[TBL] [Abstract][Full Text] [Related]
25. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
26. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness.
Yan R; Fan X; Xiao Z; Liu H; Huang X; Liu J; Zhang S; Yao J; An G; Ge Y
Cancer Lett; 2022 Apr; 531():83-97. PubMed ID: 35157971
[TBL] [Abstract][Full Text] [Related]
28. Molecular Mechanism of Mutational Disruption of DCLK1 Autoinhibition Provides a Rationale for Inhibitor Screening.
Chen W; Liu R; Yu Y; Wei D; Chen Q; Xu Q
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762326
[TBL] [Abstract][Full Text] [Related]
29. Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer.
Tao H; Tanaka T; Okabe K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1449-1459. PubMed ID: 28382517
[TBL] [Abstract][Full Text] [Related]
30. Cytoplasmic expression of DCLK1-S, a novel DCLK1 isoform, is associated with tumor aggressiveness and worse disease-specific survival in colorectal cancer.
Kalantari E; Ghods R; Saeednejad Zanjani L; Rahimi M; Eini L; Razmi M; Asadi-Lari M; Madjd Z
Cancer Biomark; 2022; 33(3):277-289. PubMed ID: 34958000
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
Park SY; Kim JY; Choi JH; Kim JH; Lee CJ; Singh P; Sarkar S; Baek JH; Nam JS
Clin Cancer Res; 2019 Feb; 25(4):1415-1429. PubMed ID: 30446587
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells.
Moore LL; Houchen CW
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003596
[TBL] [Abstract][Full Text] [Related]
33. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism.
Sureban SM; May R; Weygant N; Qu D; Chandrakesan P; Bannerman-Menson E; Ali N; Pantazis P; Westphalen CB; Wang TC; Houchen CW
Cancer Lett; 2014 Aug; 351(1):151-61. PubMed ID: 24880079
[TBL] [Abstract][Full Text] [Related]
34. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y
Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669
[TBL] [Abstract][Full Text] [Related]
35. The Essential Role of DCLK1 in Pathogenesis, Diagnostic Procedures and Prognostic Stratification of Colorectal Cancer.
Gzil A; Szylberg Ł; Jaworski D; Dominiak J; Zarębska I; Grzanka D
Anticancer Res; 2019 Jun; 39(6):2689-2697. PubMed ID: 31177103
[TBL] [Abstract][Full Text] [Related]
36. The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.
Dandawate P; Ghosh C; Palaniyandi K; Paul S; Rawal S; Pradhan R; Sayed AAA; Choudhury S; Standing D; Subramaniam D; Padhye SB; Gunewardena S; Thomas SM; Neil MO; Tawfik O; Welch DR; Jensen RA; Maliski S; Weir S; Iwakuma T; Anant S; Dhar A
Gastroenterology; 2019 Dec; 157(6):1646-1659.e11. PubMed ID: 31442435
[TBL] [Abstract][Full Text] [Related]
37. A novel antibody against cancer stem cell biomarker, DCLK1-S, is potentially useful for assessing colon cancer risk after screening colonoscopy.
Sarkar S; Popov VL; O'Connell MR; Stevenson HL; Lee BS; Obeid RA; Luthra GK; Singh P
Lab Invest; 2017 Oct; 97(10):1245-1261. PubMed ID: 28414327
[TBL] [Abstract][Full Text] [Related]
38. Doublecortin-Like Kinase 1 Facilitates Dendritic Spine Growth of Pyramidal Neurons in Mouse Prefrontal Cortex.
Murphy KE; Zhang EY; Wyatt EV; Sperringer JE; Duncan BW; Maness PF
Neuroscience; 2023 Jan; 508():98-109. PubMed ID: 36064052
[TBL] [Abstract][Full Text] [Related]
39. Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay.
Liu Y; Westover KD
STAR Protoc; 2021 Jun; 2(2):100587. PubMed ID: 34159321
[TBL] [Abstract][Full Text] [Related]
40. Doublecortin-like kinase 1 activates NF-κB to induce inflammatory responses by binding directly to IKKβ.
Luo W; Jin Y; Jiang Y; Yang L; Xu H; Wu D; Zhang Y; Yin L; Khan ZA; Liang G; Wang Y
Cell Death Differ; 2023 May; 30(5):1184-1197. PubMed ID: 36914767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
